Developer docs
API playgroundTry for free, no card

Search company profiles

Wondfo

Full company profile

uuid00soxd9

Namestring
Wondfo
Legal namestring
WONDFO BIOTECH CO., LTD.
Websiteurl
en.wondfo.com
Company typeenum
Public
Founded yearint
1992
Descriptiontext

Wondfo Biotech Co., Ltd. (Shenzhen Stock Exchange: 300482.SZ) is a China-based, publicly listed in-vitro diagnostics (IVD) company founded in 1992 and headquartered in Guangzhou Science City, operating across nine integrated technology platforms — colloidal gold, immunofluorescence (Finecare), chemiluminescence (ACCRE/SmarLumi), coagulation, blood gas, molecular diagnostics (U-CardDx 200), pathology (PA-3600 IHC), HPLC hemoglobin, and electrochemistry. Its portfolio spans rapid point-of-care testing (POCT) instruments and reagents for infectious disease (HIV, malaria, dengue, COVID-19, Mpox), chronic disease management (cardiac markers, HbA1c, coagulation), oncology and pathology, drug-of-abuse testing, and consumer diagnostics, with first-in-class products including the world's first optical coagulation analyzer testing PT/APTT/TT/FIB/ACT simultaneously and a 15-minute molecular POCT workflow.

The company monetizes primarily through sale of analyzers and recurring reagent consumables across an installed base of professional healthcare customers, supplemented by consumer-grade test kits (WELLlife COVID-19/Flu, SAFElife Fentanyl) via U.S. e-commerce and pharmacy channels, and by global public-health procurement of WHO-prequalified HIV and malaria products. Go-to-market combines 20+ wholly-owned subsidiaries (recent additions: Russia April 2025, Philippines April 2025, Malaysia July 2025), a distributor network spanning 150+ countries, and localized manufacturing partnerships in Uganda and Nigeria. R&D intensity is high at RMB 438 million in 2024 (14.3% of revenue), and the company maintains regulatory moats including WHO prequalification, IVDR CE certification, FDA 510(k)/EUA approvals, IFCC membership, and 12 items on the JCTLM Reference Measurement Services list.

FY2024 revenue was RMB 3.065 billion (~USD 420 million, +10.85% YoY) with net profit of RMB 562 million; FY2025 revenue fell to RMB 2.087 billion (~USD 287 million) with a net loss of RMB 63 million, reflecting industry-wide IVD demand normalization. Leadership includes Founder Wenmei Li and Chairwoman Jihua Wang, with President Zhongxiong Peng, VP/Head of International Sales & Marketing Mark Xu, and General Manager of Wondfo Health Yunping Peng. The balance sheet remains conservative, with RMB 1.971 billion in cash and trading financial assets and an ~17% asset-liability ratio as of Q1 2026.

Short descriptiontext

Wondfo is a publicly listed Chinese IVD company operating 9 POCT technology platforms — colloidal gold, immunofluorescence, chemiluminescence, coagulation, blood gas, molecular, pathology, HPLC, and electrochemistry — serving hospitals, public-health programs, and consumers in 150+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersGuangzhou, China
HQ citystring
Guangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro diagnostics, point-of-care testing, rapid diagnostic tests, chemiluminescence immunoassays, molecular diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In Vitro Diagnostics
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1POCT Instruments and Reagents
TypeHardware Sales
Description

Wondfo generates revenue primarily from selling rapid diagnostic devices (analyzers) and associated reagent kits across its 9 technology platforms. The company derives recurring revenue from reagent consumption across installed instrument bases. Key product categories include immunofluorescence analyzers (Finecare series), chemiluminescence analyzers (ACCRE, SmarLumi), blood gas analyzers, coagulation analyzers, molecular diagnostic systems, and pathology staining systems.

en.wondfo.com
2Consumer/Direct-to-Consumer Diagnostics
TypeOne Time License
Description

Revenue from consumer-grade diagnostic products sold via e-commerce and pharmacy channels, including the FDA-approved WELLlife™ COVID-19/Flu A&B Home Test and SAFElife™ Fentanyl Urine Test in the U.S. market.

en.wondfo.com
3Public Health and Government Procurement
TypeOne Time License
Description

Revenue from inclusion of colloidal gold public health products in national procurement guidelines, and WHO prequalified products (HIV, Malaria) procured by global health organizations.

en.wondfo.com
4Local Manufacturing and Technology Transfer
TypeLicensing Royalties
Description

Revenue from localized production partnerships including plants in Uganda (Microhaem Scientifics), Nigeria (PVAC agreement), and other developing countries, where Wondfo provides technical assistance and manufacturing know-how for local production of diagnostic reagents.

en.wondfo.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1Finecare
Description

Immunofluorescence platform for rapid diagnostics including cardiovascular disease, inflammation, kidney injury, and other markers

en.wondfo.com
+9 more records
Core offering1 text field

Wondfo develops and manufactures in vitro diagnostic (IVD) devices and reagents organized around nine proprietary technology platforms — Colloidal Gold, Immunofluorescence (Finecare), Chemiluminescence (ACCRE/SmarLumi), Coagulation, Blood Gas, Molecular Diagnostics, Pathology, HPLC Hemoglobin, and Electrochemistry — for point-of-care testing across infectious disease, cardiovascular, diabetes, oncology, fertility, drug-of-abuse, and chronic disease applications. The company also sells FDA-cleared consumer diagnostics (WELLlife COVID-19/Flu Home Test, SAFElife Fentanyl Test) in North America, and partners with global health programs for WHO-prequalified HIV and Malaria tests. Revenue is generated through instrument sales, recurring reagent consumption, government and WHO procurement, technology transfer/licensing for local production, and B2C retail sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • R&D investment of RMB 438 million (14.3% of revenue) in 2024, launching 82 new products (75 reagents, 7 devices)
+4 more records
Product overview1 text field

Wondfo Biotech is a leading POCT (Point-of-Care Testing) company specializing in the IVD (In Vitro Diagnostics) industry. Founded in 1992 and headquartered in Guangzhou Science City, the company offers a comprehensive portfolio organized around 9 technology platforms: Colloidal Gold, Immunofluorescence (Finecare), Chemiluminescence (ACCRE/SmarLumi), Coagulation, Blood Gas (BGA-102/Ucare-6000), Molecular Diagnostics (U-CardDx 200, RT-PCR), Pathology (PA-3600 IHC Staining System), HPLC Hemoglobin (Truth-H80E), and Electrochemistry. The product portfolio includes rapid diagnostic devices and reagents spanning cardiovascular diseases, diabetes, renal functions, respiratory issues, fertility, drug abuse, infections, tumors, and more. Key instruments include the SmarLumi FC-2100, Accre series (8/90/120), Finecare FIA platforms (FS-1000/FS-2000), U-CardDx 200 molecular diagnostics, and PA-3600 pathology system. The company provides solutions for clinical diagnostics, public health, chronic disease management, and consumer/home diagnostics, serving over 150 countries and regions worldwide.

Product and service24 records
1Colloidal Gold Platform
CategoryIn Vitro Diagnostics — Colloidal Gold Rapid Tests
Description

Equipment-free rapid immunochromatographic diagnostic platform used for infectious disease (HIV, malaria, dengue), fertility, and drug-of-abuse testing in clinical, public health, and consumer settings.

2Immunofluorescence (Finecare) Platform
CategoryIn Vitro Diagnostics — Immunofluorescence Immunoassays
Description

Quantitative fluorescence immunoassay platform with 50+ reagents and seven high-performance analyzers (FS-1000, FS-2000, FS-114, FS-2100) for cardiovascular, inflammation, kidney injury, sex hormone, thyroid, diabetes, and tumor markers at point-of-care.

3Chemiluminescence (ACCRE / SmarLumi) Platform
CategoryIn Vitro Diagnostics — Chemiluminescence Immunoassays
Description

Single-dose chemiluminescence immunoassay platform with maintenance-free operation, carry-over prevention, 600-day MTBF, and nearly 100 testing parameters covering tumor markers, thyroid, cardiac, inflammation, coagulation, and chronic disease markers.

4Coagulation Platform (Optical Blood Coagulation Analyzer)
CategoryIn Vitro Diagnostics — Coagulation Analyzers
Description

Optical blood coagulation analyzer testing PT, APTT, TT, FIB, and ACT simultaneously — the first of its kind in the world — plus a Thrombosis 4-Item Test (TAT, TM, PIC, t-PAIC) for early thrombosis screening.

5Blood Gas Platform (BGA-102 / Ucare-6000)
CategoryIn Vitro Diagnostics — Blood Gas Analyzers
Description

Blood gas analyzer for emergency, ICU, and laboratory use. BGA-102 delivers results in 30 seconds; Ucare-6000 features an all-in-one reagent pack with automated calibration and IQC for full-panel results in one step.

6U-CardDx 200 Molecular POCT System
CategoryIn Vitro Diagnostics — Molecular Diagnostics
Description

Microfluidics-based molecular point-of-care solution using magnetic bead nucleic acid extraction and real-time qPCR with lyophilized ready-to-use reagents; delivers a full workflow in 15 minutes with 200 copies/mL sensitivity for infectious disease testing.

7WonNova 1600 Fully Automated Nucleic Acid Extraction and Real-Time PCR System
CategoryIn Vitro Diagnostics — Molecular Diagnostics
Description

Fully automated nucleic acid extraction and real-time PCR system for molecular diagnostics, targeting centralized laboratory use with NMPA approval.

8PA-3600 IHC Staining System (Pathology Platform)
CategoryIn Vitro Diagnostics — Pathology / IHC Staining
Description

Fully automated immunohistochemistry staining system with patented per-slide temperature control, solid-liquid cover technology, wavelike-mixing technology, RFID chip recognition, and ultra-sensitive HRP enzyme-conjugated 'clover-like' secondary antibodies; supports IHC, ISH, and FISH applications.

9Truth-H80E HPLC Hemoglobin Analyzer
CategoryIn Vitro Diagnostics — HPLC Diabetes Diagnostics
Description

HPLC-based analyzer for precise measurement of glycosylated hemoglobin (HbA1c) — the gold standard for diabetes diagnosis — with results in 60–90 seconds and a chromatography column usable up to 2,000 times.

10SmarLumi FC-2100 Chemiluminescence Immunoassay Analyzer
CategoryIn Vitro Diagnostics — Chemiluminescence Analyzer
Description

Fully-automatic bench-top chemiluminescence immunoassay analyzer with 0.64 sqm footprint, 60 sample positions, 25 reagent positions, 200 tests/hour throughput, and first results in 12 minutes for hospital laboratories.

11Accre 120 Automatic Chemiluminescence Immunoassay Analyzer
CategoryIn Vitro Diagnostics — Chemiluminescence Analyzer
Description

Bench-top automatic chemiluminescence immunoassay analyzer with single-dose reagent cartridge, maintenance-free design, 600-day MTBF, and compact footprint (570x685x740mm, 100kg) for mid-volume laboratories.

12Accre 90 Automatic Chemiluminescence Immunoassay Analyzer
CategoryIn Vitro Diagnostics — Chemiluminescence Analyzer
Description

Compact bench-top automatic chemiluminescence immunoassay analyzer with single-dose reagent cartridge, up to 96 tests/hour, and 600-day MTBF (566x524x672mm, 67kg).

13Accre 8 Compact Chemiluminescence Immunoassay Analyzer
CategoryIn Vitro Diagnostics — Chemiluminescence Analyzer
Description

Compact automatic bench-top CLIA analyzer with single-dose reagent cartridge, up to 36 tests/hour, 12–40 minute TAT, and a footprint 70% smaller than ordinary CLIA analyzers for low-volume point-of-care settings.

14FS-1000 Fluorescence Immunoassay Analyzer
CategoryIn Vitro Diagnostics — Immunofluorescence Analyzer
Description

Upgraded fluorescence immunoassay analyzer with one-step barcode scanning, whole-blood one-step sample addition, built-in lithium battery with 12-hour standby, and high-sensitivity cardiac troponin I results in 8 minutes.

15FS-2000 Fluorescence Immunoassay Analyzer
CategoryIn Vitro Diagnostics — Immunofluorescence Analyzer
Description

Multi-channel fluorescence immunoassay analyzer with enhanced specificity, improved stability, and rapid testing mode for urgent diagnostic needs in clinical and emergency settings.

16WELLlife COVID-19/Flu A&B Home Test
CategoryConsumer Diagnostics — Respiratory Home Test
Description

FDA EUA- and 510(k)-cleared at-home rapid antigen test for COVID-19 and Influenza A&B, sold via e-commerce and pharmacy channels in North America.

17SAFElife Fentanyl Urine Test
CategoryConsumer Diagnostics — Drug of Abuse
Description

FDA 510(k)-cleared urine test for fentanyl detection, sold through U.S. e-commerce and pharmacy channels as part of Wondfo's drug-of-abuse consumer diagnostics line.

18Malaria P.f (HRP2/pLDH) Test
CategoryIn Vitro Diagnostics — Infectious Disease Rapid Test
Description

Colloidal gold immunochromatographic test for qualitative detection of Plasmodium falciparum HRP2 and pLDH antigens in whole blood; WHO-prequalified for global public health procurement.

19One Step HIV Self-Testing Kit
CategoryIn Vitro Diagnostics — Infectious Disease Self-Test
Description

WHO-prequalified single-use HIV self-testing kit using finger-stick whole blood with results in 15 minutes, distributed through public health programs and global procurement channels.

20Mpox (Monkeypox) Virus Real-Time PCR Assay and U-Card Dx Mpox Test
CategoryIn Vitro Diagnostics — Molecular Infectious Disease
Description

PCR-based nucleic acid detection assays for Monkeypox virus from skin lesion tissues, throat swabs, whole blood, and serum, supporting outbreak surveillance and clinical diagnosis.

21Dengue Virus Testing Reagents
CategoryIn Vitro Diagnostics — Infectious Disease Rapid Test
Description

Combined dengue virus antigen and antibody rapid test for quick determination of dengue infection status and disease progression, used in clinical and public health settings in endemic regions.

22Thrombosis 4-Item Test (TAT, TM, PIC, t-PAIC)
CategoryIn Vitro Diagnostics — Coagulation Reagent
Description

Early screening panel for thrombosis combining TAT, TM, PIC, and t-PAIC markers, run on the Wondfo coagulation platform for VTE prevention and emergency diagnostics.

23Finecare hs-cTnI (High-Sensitivity Cardiac Troponin I) Test
CategoryIn Vitro Diagnostics — Cardiac Marker Reagent
Description

High-sensitivity cardiac troponin I test for Finecare analyzers with detection limit as low as 20 pg/mL and 8-minute results, supporting rapid rule-in/rule-out of myocardial infarction in emergency departments.

24Finecare Vitamin D Test
CategoryIn Vitro Diagnostics — Endocrinology Reagent
Description

Quantitative Finecare platform-based Vitamin D test for nutritional assessment and primary care support, designed to simplify vitamin D status measurement.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1Shanghai Kinbio Biotech Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-02
Description

Wondfo and Kinbio signed a strategic cooperation agreement for global localized production of rapid diagnostic reagents. The partnership integrates Wondfo's biotechnology expertise with Kinbio's IVD production line automation capabilities to provide international partners with one-stop production and distribution solutions.

en.wondfo.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Wondfo was among the global pharmaceutical and diagnostic companies that signed at least 10 strategic MoUs with the Nigerian government following federal policies introduced in 2023 after multinational pharma exits. These partnerships aim to strengthen Nigeria's pharmaceutical sector and support local manufacturing of diagnostic products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MedAccess, a non-profit focused on enhancing medical product accessibility in low and middle-income countries, partnered with Wondfo (along with CHAI) to provide HIV self-testing products for low-income regions in Africa. Discussions are ongoing for malaria product cooperation following WHO PQ certification of Wondfo's malaria test.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Wondfo hosted the Conference on Evaluation Results of Rapid Diagnostic Tests in Côte d'Ivoire, bringing together laboratory experts and public health professionals from West African countries. Wondfo signed a strategic agreement with Côte d'Ivoire's Ministry of Health for future local technology transfer, cooperating in Industry–Academia–Research–Application to expand access to high-quality diagnostic products across ECOWAS.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Delegations from the United Nations Economic Commission for Africa (UNECA) and African Union Commission visited Wondfo to learn about innovative IVD practices. UNECA Healthcare Center has already introduced Wondfo's quantitative fluorescence system for cardiac marker testing, with the lab now having six installations. Both organizations aim to upgrade healthcare services in African countries using Wondfo's advanced experiences and technologies.

6Universiti Sains Malaysia (USM)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Wondfo signed an MOU with Universiti Sains Malaysia (USM), a top-tier university ranked in the top 1% globally, to strengthen collaboration in academic exchanges and accelerate the transformation of scientific research achievements. Wondfo and USM will collaborate on clinical research projects, joint product development, and educational innovation. Wondfo had already begun scientific research cooperation with USM in 2022 on POCT applications in critical care.

en.wondfo.com
7Uganda Ministry of Health and Kampala Capital City Authority (KCCA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Wondfo launched a pioneering HIV self-testing campaign in partnership with Uganda's Ministry of Health and KCCA, targeting bodaboda riders and market vendors. The campaign distributes user-friendly, single-use test kits providing results in 15 minutes, along with counseling services and educational resources delivered directly to urban communities via audiovisual trucks and on-the-ground teams.

en.wondfo.com
8International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Wondfo became an official member of IFCC in 2024, committed to enhancing communication with international experts and participating in the research and development of international standards to contribute to global laboratory medicine standardization. Wondfo's Reference Systems Department promotes measurement traceability from SI reference laboratories to clinical laboratories.

en.wondfo.com
9University of Technology Malaysia (UTM)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

UTM conducted a clinical study validating Wondfo's quantitative Fluorescence Detection System for PCT testing in sepsis ICU patients. The study, published in the journal Diagnostics, showed a correlation coefficient of 0.98 between Wondfo's system and the world's leading biochemical immunoassay system, demonstrating robust performance for critically ill sepsis monitoring.

en.wondfo.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CHAI partnered with Wondfo and MedAccess in 2022 to provide HIV self-testing products for low-income regions, benefiting a wider population and actively supporting global AIDS prevention efforts across Africa.

11Nigerian Presidential Initiative on Healthcare Value Chain (PVAC)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Wondfo signed a cooperation agreement with the Nigerian Presidential Initiative on Healthcare Value Chain (PVAC) in August 2024. The Nigerian government provides policy, financial, and infrastructure support to facilitate local production of Wondfo's diagnostic reagents, enhancing Wondfo's supply chain resilience across Africa.

en.wondfo.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Wondfo provided full technical assistance for the establishment of the Uganda Diagnostic Reagent Manufacturing Plant, Microhaem Scientifics, inaugurated in November 2023. The plant benefits over 300 million people and serves as a model for Wondfo's localized production strategy in Africa.

13European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Wondfo served as Silver Partner at the EFLM Strategic Conference 2026 in Prague, strengthening engagement with the global laboratory medicine community. Discussions covered testing efficiency, decentralized diagnostics, and emerging clinical applications.

en.wondfo.com
14European, Middle Eastern, and Other International Partners (Molecular Diagnostics)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

During ESCMID 2026, Wondfo entered into strategic cooperation agreements with partners across Europe, the Middle East, and other regions to strengthen its position in the global molecular diagnostics market and support the commercialization of the U-CardDx 200 molecular POCT system.

en.wondfo.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

US-based IVD company with strong rapid diagnostics franchise (Sofia, Triage, QuickVue) plus a broader clinical chemistry and immunoassay business — comparable to Wondfo in rapid infectious disease and cardiac marker POCT.

2Abbott Diagnostics
TypeBroad incumbent
Description

Global diagnostics leader with the broadest IVD and POCT portfolio (including former Alere assets) spanning immunoassay, molecular, blood gas, and consumer diagnostics — competes head-to-head with Wondfo across most platform categories.

TypeDirect peer
Description

US-headquartered IVD and POCT company with a comparable portfolio of rapid diagnostic tests across infectious disease, fertility, drugs of abuse, and clinical chemistry — overlapping directly with Wondfo's colloidal gold and consumer diagnostic lines.

4Boditech Med
TypeDirect peer
Description

Korean POCT company focused on immunofluorescence and clinical chemistry analyzers with reagent menus spanning cardiovascular, inflammation, infectious disease, and hormones — directly comparable to Wondfo's Finecare platform.

TypeDirect peer
Description

Korean IVD/POCT specialist with strong overlap in immunofluorescence, rapid antigen tests, and infectious disease diagnostics — a close product-line competitor to Wondfo, especially in Africa and Southeast Asia.

TypeBroad incumbent
Description

US diagnostics and women's health specialist with molecular diagnostics (Panther), cytology/HPV testing, and rapid antigen tests — comparable to Wondfo in molecular POCT and select women's health/oncology adjacencies.

TypeBroad incumbent
Description

Diversified life science and clinical diagnostics company with quality controls, blood bank reagents, and digital PCR — overlaps with Wondfo's molecular diagnostics and laboratory QC/reference measurement services.

TypeBroad incumbent
Description

Major global diagnostics and imaging incumbent with significant POCT and immunoassay presence (Atellica, epoc) — directly competes with Wondfo in chemiluminescence, blood gas, and immunochemistry hospital segments.

TypeBroad incumbent
Description

World's largest IVD player with extensive central-lab and POCT offerings across immunoassay, clinical chemistry, molecular diagnostics, and coagulation — overlaps with Wondfo's chemiluminescence, coagulation, and molecular diagnostics lines.

TypeDirect peer
Description

China-based IVD/POCT competitor with leadership in blood glucose monitoring and a growing portfolio in infectious disease and chronic disease diagnostics — overlaps with Wondfo's domestic Chinese POCT positioning and consumer health (Wondfo Health) initiatives.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wondfo

In Vitro Diagnosticsen.wondfo.com

Wondfo is a publicly listed Chinese IVD company operating 9 POCT technology platforms — colloidal gold, immunofluorescence, chemiluminescence, coagulation, blood gas, molecular, pathology, HPLC, and electrochemistry — serving hospitals, public-health programs, and consumers in 150+ countries.

What Wondfo does

Wondfo Biotech Co., Ltd. (Shenzhen Stock Exchange: 300482.SZ) is a China-based, publicly listed in-vitro diagnostics (IVD) company founded in 1992 and headquartered in Guangzhou Science City, operating across nine integrated technology platforms — colloidal gold, immunofluorescence (Finecare), chemiluminescence (ACCRE/SmarLumi), coagulation, blood gas, molecular diagnostics (U-CardDx 200), pathology (PA-3600 IHC), HPLC hemoglobin, and electrochemistry. Its portfolio spans rapid point-of-care testing (POCT) instruments and reagents for infectious disease (HIV, malaria, dengue, COVID-19, Mpox), chronic disease management (cardiac markers, HbA1c, coagulation), oncology and pathology, drug-of-abuse testing, and consumer diagnostics, with first-in-class products including the world's first optical coagulation analyzer testing PT/APTT/TT/FIB/ACT simultaneously and a 15-minute molecular POCT workflow.

The company monetizes primarily through sale of analyzers and recurring reagent consumables across an installed base of professional healthcare customers, supplemented by consumer-grade test kits (WELLlife COVID-19/Flu, SAFElife Fentanyl) via U.S. e-commerce and pharmacy channels, and by global public-health procurement of WHO-prequalified HIV and malaria products. Go-to-market combines 20+ wholly-owned subsidiaries (recent additions: Russia April 2025, Philippines April 2025, Malaysia July 2025), a distributor network spanning 150+ countries, and localized manufacturing partnerships in Uganda and Nigeria. R&D intensity is high at RMB 438 million in 2024 (14.3% of revenue), and the company maintains regulatory moats including WHO prequalification, IVDR CE certification, FDA 510(k)/EUA approvals, IFCC membership, and 12 items on the JCTLM Reference Measurement Services list.

FY2024 revenue was RMB 3.065 billion (~USD 420 million, +10.85% YoY) with net profit of RMB 562 million; FY2025 revenue fell to RMB 2.087 billion (~USD 287 million) with a net loss of RMB 63 million, reflecting industry-wide IVD demand normalization. Leadership includes Founder Wenmei Li and Chairwoman Jihua Wang, with President Zhongxiong Peng, VP/Head of International Sales & Marketing Mark Xu, and General Manager of Wondfo Health Yunping Peng. The balance sheet remains conservative, with RMB 1.971 billion in cash and trading financial assets and an ~17% asset-liability ratio as of Q1 2026.

Wondfo firmographics

Firmographics
Name
Wondfo
Legal name
WONDFO BIOTECH CO., LTD.
Website
https://en.wondfo.com
Company type
Public
Founded year
1992
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Wondfo is a publicly listed Chinese IVD company operating 9 POCT technology platforms — colloidal gold, immunofluorescence, chemiluminescence, coagulation, blood gas, molecular, pathology, HPLC, and electrochemistry — serving hospitals, public-health programs, and consumers in 150+ countries.
Ownership category
akta.pro rank

Where Wondfo is headquartered

Location

Headquarters

HQ city
Guangzhou
HQ country
China
HQ region
Asia

Offices7 records

Markets served

Wondfo business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. POCT Instruments and Reagents: Wondfo generates revenue primarily from selling rapid diagnostic devices (analyzers) and associated reagent kits across its 9 technology platforms. The company derives recurring revenue from reagent consumption across installed instrument bases. Key product categories include immunofluorescence analyzers (Finecare series), chemiluminescence analyzers (ACCRE, SmarLumi), blood gas analyzers, coagulation analyzers, molecular diagnostic systems, and pathology staining systems.
  2. Consumer/Direct-to-Consumer Diagnostics: Revenue from consumer-grade diagnostic products sold via e-commerce and pharmacy channels, including the FDA-approved WELLlife™ COVID-19/Flu A&B Home Test and SAFElife™ Fentanyl Urine Test in the U.S. market.
  3. Public Health and Government Procurement: Revenue from inclusion of colloidal gold public health products in national procurement guidelines, and WHO prequalified products (HIV, Malaria) procured by global health organizations.
  4. Local Manufacturing and Technology Transfer: Revenue from localized production partnerships including plants in Uganda (Microhaem Scientifics), Nigeria (PVAC agreement), and other developing countries, where Wondfo provides technical assistance and manufacturing know-how for local production of diagnostic reagents.

Go-to-market motion4 records

Distribution channels6 records

Marketing channels9 records

Wondfo product offering

Product offering

Core offering

Wondfo develops and manufactures in vitro diagnostic (IVD) devices and reagents organized around nine proprietary technology platforms — Colloidal Gold, Immunofluorescence (Finecare), Chemiluminescence (ACCRE/SmarLumi), Coagulation, Blood Gas, Molecular Diagnostics, Pathology, HPLC Hemoglobin, and Electrochemistry — for point-of-care testing across infectious disease, cardiovascular, diabetes, oncology, fertility, drug-of-abuse, and chronic disease applications. The company also sells FDA-cleared consumer diagnostics (WELLlife COVID-19/Flu Home Test, SAFElife Fentanyl Test) in North America, and partners with global health programs for WHO-prequalified HIV and Malaria tests. Revenue is generated through instrument sales, recurring reagent consumption, government and WHO procurement, technology transfer/licensing for local production, and B2C retail sales.

Product overview

Wondfo Biotech is a leading POCT (Point-of-Care Testing) company specializing in the IVD (In Vitro Diagnostics) industry. Founded in 1992 and headquartered in Guangzhou Science City, the company offers a comprehensive portfolio organized around 9 technology platforms: Colloidal Gold, Immunofluorescence (Finecare), Chemiluminescence (ACCRE/SmarLumi), Coagulation, Blood Gas (BGA-102/Ucare-6000), Molecular Diagnostics (U-CardDx 200, RT-PCR), Pathology (PA-3600 IHC Staining System), HPLC Hemoglobin (Truth-H80E), and Electrochemistry. The product portfolio includes rapid diagnostic devices and reagents spanning cardiovascular diseases, diabetes, renal functions, respiratory issues, fertility, drug abuse, infections, tumors, and more. Key instruments include the SmarLumi FC-2100, Accre series (8/90/120), Finecare FIA platforms (FS-1000/FS-2000), U-CardDx 200 molecular diagnostics, and PA-3600 pathology system. The company provides solutions for clinical diagnostics, public health, chronic disease management, and consumer/home diagnostics, serving over 150 countries and regions worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • Finecare: Immunofluorescence platform for rapid diagnostics including cardiovascular disease, inflammation, kidney injury, and other markers
  • SmarLumi
  • ACCRE
  • Ucare
  • WELLlife
  • SAFElife
  • U-CardDx
  • WonNova
  • Truth-H80E
  • PA-3600

Products and services

  • Colloidal Gold Platform Equipment-free rapid immunochromatographic diagnostic platform used for infectious disease (HIV, malaria, dengue), fertility, and drug-of-abuse testing in clinical, public health, and consumer settings.
  • Immunofluorescence (Finecare) Platform Quantitative fluorescence immunoassay platform with 50+ reagents and seven high-performance analyzers (FS-1000, FS-2000, FS-114, FS-2100) for cardiovascular, inflammation, kidney injury, sex hormone, thyroid, diabetes, and tumor markers at point-of-care.
  • Chemiluminescence (ACCRE / SmarLumi) Platform Single-dose chemiluminescence immunoassay platform with maintenance-free operation, carry-over prevention, 600-day MTBF, and nearly 100 testing parameters covering tumor markers, thyroid, cardiac, inflammation, coagulation, and chronic disease markers.
  • Coagulation Platform (Optical Blood Coagulation Analyzer) Optical blood coagulation analyzer testing PT, APTT, TT, FIB, and ACT simultaneously — the first of its kind in the world — plus a Thrombosis 4-Item Test (TAT, TM, PIC, t-PAIC) for early thrombosis screening.
  • Blood Gas Platform (BGA-102 / Ucare-6000) Blood gas analyzer for emergency, ICU, and laboratory use. BGA-102 delivers results in 30 seconds; Ucare-6000 features an all-in-one reagent pack with automated calibration and IQC for full-panel results in one step.
  • U-CardDx 200 Molecular POCT System Microfluidics-based molecular point-of-care solution using magnetic bead nucleic acid extraction and real-time qPCR with lyophilized ready-to-use reagents; delivers a full workflow in 15 minutes with 200 copies/mL sensitivity for infectious disease testing.
  • WonNova 1600 Fully Automated Nucleic Acid Extraction and Real-Time PCR System Fully automated nucleic acid extraction and real-time PCR system for molecular diagnostics, targeting centralized laboratory use with NMPA approval.
  • PA-3600 IHC Staining System (Pathology Platform) Fully automated immunohistochemistry staining system with patented per-slide temperature control, solid-liquid cover technology, wavelike-mixing technology, RFID chip recognition, and ultra-sensitive HRP enzyme-conjugated 'clover-like' secondary antibodies; supports IHC, ISH, and FISH applications.
  • Truth-H80E HPLC Hemoglobin Analyzer HPLC-based analyzer for precise measurement of glycosylated hemoglobin (HbA1c) — the gold standard for diabetes diagnosis — with results in 60–90 seconds and a chromatography column usable up to 2,000 times.
  • SmarLumi FC-2100 Chemiluminescence Immunoassay Analyzer Fully-automatic bench-top chemiluminescence immunoassay analyzer with 0.64 sqm footprint, 60 sample positions, 25 reagent positions, 200 tests/hour throughput, and first results in 12 minutes for hospital laboratories.
  • Accre 120 Automatic Chemiluminescence Immunoassay Analyzer Bench-top automatic chemiluminescence immunoassay analyzer with single-dose reagent cartridge, maintenance-free design, 600-day MTBF, and compact footprint (570x685x740mm, 100kg) for mid-volume laboratories.
  • Accre 90 Automatic Chemiluminescence Immunoassay Analyzer Compact bench-top automatic chemiluminescence immunoassay analyzer with single-dose reagent cartridge, up to 96 tests/hour, and 600-day MTBF (566x524x672mm, 67kg).
  • Accre 8 Compact Chemiluminescence Immunoassay Analyzer Compact automatic bench-top CLIA analyzer with single-dose reagent cartridge, up to 36 tests/hour, 12–40 minute TAT, and a footprint 70% smaller than ordinary CLIA analyzers for low-volume point-of-care settings.
  • FS-1000 Fluorescence Immunoassay Analyzer Upgraded fluorescence immunoassay analyzer with one-step barcode scanning, whole-blood one-step sample addition, built-in lithium battery with 12-hour standby, and high-sensitivity cardiac troponin I results in 8 minutes.
  • FS-2000 Fluorescence Immunoassay Analyzer Multi-channel fluorescence immunoassay analyzer with enhanced specificity, improved stability, and rapid testing mode for urgent diagnostic needs in clinical and emergency settings.
  • WELLlife COVID-19/Flu A&B Home Test FDA EUA- and 510(k)-cleared at-home rapid antigen test for COVID-19 and Influenza A&B, sold via e-commerce and pharmacy channels in North America.
  • SAFElife Fentanyl Urine Test FDA 510(k)-cleared urine test for fentanyl detection, sold through U.S. e-commerce and pharmacy channels as part of Wondfo's drug-of-abuse consumer diagnostics line.
  • Malaria P.f (HRP2/pLDH) Test Colloidal gold immunochromatographic test for qualitative detection of Plasmodium falciparum HRP2 and pLDH antigens in whole blood; WHO-prequalified for global public health procurement.
  • One Step HIV Self-Testing Kit WHO-prequalified single-use HIV self-testing kit using finger-stick whole blood with results in 15 minutes, distributed through public health programs and global procurement channels.
  • Mpox (Monkeypox) Virus Real-Time PCR Assay and U-Card Dx Mpox Test PCR-based nucleic acid detection assays for Monkeypox virus from skin lesion tissues, throat swabs, whole blood, and serum, supporting outbreak surveillance and clinical diagnosis.
  • Dengue Virus Testing Reagents Combined dengue virus antigen and antibody rapid test for quick determination of dengue infection status and disease progression, used in clinical and public health settings in endemic regions.
  • Thrombosis 4-Item Test (TAT, TM, PIC, t-PAIC) Early screening panel for thrombosis combining TAT, TM, PIC, and t-PAIC markers, run on the Wondfo coagulation platform for VTE prevention and emergency diagnostics.
  • Finecare hs-cTnI (High-Sensitivity Cardiac Troponin I) Test High-sensitivity cardiac troponin I test for Finecare analyzers with detection limit as low as 20 pg/mL and 8-minute results, supporting rapid rule-in/rule-out of myocardial infarction in emergency departments.
  • Finecare Vitamin D Test Quantitative Finecare platform-based Vitamin D test for nutritional assessment and primary care support, designed to simplify vitamin D status measurement.

Quantifiable outcome

  • R&D investment of RMB 438 million (14.3% of revenue) in 2024, launching 82 new products (75 reagents, 7 devices)
  • +4 more outcomes

Companies that use Wondfo

Customer profile

Named customers9 records

Segments6 records

Ideal customer profiles5 records

Wondfo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Wondfo partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • Shanghai Kinbio Biotech Co., Ltd.coreStrategic or Co-development Partner · 2 July 2025Wondfo and Kinbio signed a strategic cooperation agreement for global localized production of rapid diagnostic reagents. The partnership integrates Wondfo's biotechnology expertise with Kinbio's IVD production line automation capabilities to provide international partners with one-stop production and distribution solutions.
  • Vestergaard, Abbott, Siemens Healthineers, ZiplinecoreStrategic or Co-development PartnerWondfo was among the global pharmaceutical and diagnostic companies that signed at least 10 strategic MoUs with the Nigerian government following federal policies introduced in 2023 after multinational pharma exits. These partnerships aim to strengthen Nigeria's pharmaceutical sector and support local manufacturing of diagnostic products.
  • MedAccesscoreStrategic or Co-development PartnerMedAccess, a non-profit focused on enhancing medical product accessibility in low and middle-income countries, partnered with Wondfo (along with CHAI) to provide HIV self-testing products for low-income regions in Africa. Discussions are ongoing for malaria product cooperation following WHO PQ certification of Wondfo's malaria test.
  • Côte d'Ivoire Ministry of HealthcoreStrategic or Co-development PartnerWondfo hosted the Conference on Evaluation Results of Rapid Diagnostic Tests in Côte d'Ivoire, bringing together laboratory experts and public health professionals from West African countries. Wondfo signed a strategic agreement with Côte d'Ivoire's Ministry of Health for future local technology transfer, cooperating in Industry–Academia–Research–Application to expand access to high-quality diagnostic products across ECOWAS.
  • UNECA Healthcare Center and African Union CommissioncoreStrategic or Co-development PartnerDelegations from the United Nations Economic Commission for Africa (UNECA) and African Union Commission visited Wondfo to learn about innovative IVD practices. UNECA Healthcare Center has already introduced Wondfo's quantitative fluorescence system for cardiac marker testing, with the lab now having six installations. Both organizations aim to upgrade healthcare services in African countries using Wondfo's advanced experiences and technologies.
  • Universiti Sains Malaysia (USM)minorStrategic or Co-development PartnerWondfo signed an MOU with Universiti Sains Malaysia (USM), a top-tier university ranked in the top 1% globally, to strengthen collaboration in academic exchanges and accelerate the transformation of scientific research achievements. Wondfo and USM will collaborate on clinical research projects, joint product development, and educational innovation. Wondfo had already begun scientific research cooperation with USM in 2022 on POCT applications in critical care.
  • Uganda Ministry of Health and Kampala Capital City Authority (KCCA)coreStrategic or Co-development PartnerWondfo launched a pioneering HIV self-testing campaign in partnership with Uganda's Ministry of Health and KCCA, targeting bodaboda riders and market vendors. The campaign distributes user-friendly, single-use test kits providing results in 15 minutes, along with counseling services and educational resources delivered directly to urban communities via audiovisual trucks and on-the-ground teams.
  • International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)coreStrategic or Co-development PartnerWondfo became an official member of IFCC in 2024, committed to enhancing communication with international experts and participating in the research and development of international standards to contribute to global laboratory medicine standardization. Wondfo's Reference Systems Department promotes measurement traceability from SI reference laboratories to clinical laboratories.
  • University of Technology Malaysia (UTM)minorStrategic or Co-development PartnerUTM conducted a clinical study validating Wondfo's quantitative Fluorescence Detection System for PCT testing in sepsis ICU patients. The study, published in the journal Diagnostics, showed a correlation coefficient of 0.98 between Wondfo's system and the world's leading biochemical immunoassay system, demonstrating robust performance for critically ill sepsis monitoring.
  • Clinton Health Access Initiative (CHAI)coreStrategic or Co-development PartnerCHAI partnered with Wondfo and MedAccess in 2022 to provide HIV self-testing products for low-income regions, benefiting a wider population and actively supporting global AIDS prevention efforts across Africa.
  • Nigerian Presidential Initiative on Healthcare Value Chain (PVAC)coreStrategic or Co-development PartnerWondfo signed a cooperation agreement with the Nigerian Presidential Initiative on Healthcare Value Chain (PVAC) in August 2024. The Nigerian government provides policy, financial, and infrastructure support to facilitate local production of Wondfo's diagnostic reagents, enhancing Wondfo's supply chain resilience across Africa.
  • Microhaem Scientifics (Uganda)coreStrategic or Co-development PartnerWondfo provided full technical assistance for the establishment of the Uganda Diagnostic Reagent Manufacturing Plant, Microhaem Scientifics, inaugurated in November 2023. The plant benefits over 300 million people and serves as a model for Wondfo's localized production strategy in Africa.
  • European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)minorStrategic or Co-development PartnerWondfo served as Silver Partner at the EFLM Strategic Conference 2026 in Prague, strengthening engagement with the global laboratory medicine community. Discussions covered testing efficiency, decentralized diagnostics, and emerging clinical applications.
  • European, Middle Eastern, and Other International Partners (Molecular Diagnostics)minorStrategic or Co-development PartnerDuring ESCMID 2026, Wondfo entered into strategic cooperation agreements with partners across Europe, the Middle East, and other regions to strengthen its position in the global molecular diagnostics market and support the commercialization of the U-CardDx 200 molecular POCT system.

Scale indicators16 records

Recent moves10 records

Expansion highlights6 records

Wondfo competitors and assessment

Company assessment

Broad incumbents

  • QuidelOrtho: US-based IVD company with strong rapid diagnostics franchise (Sofia, Triage, QuickVue) plus a broader clinical chemistry and immunoassay business — comparable to Wondfo in rapid infectious disease and cardiac marker POCT.
  • Abbott Diagnostics: Global diagnostics leader with the broadest IVD and POCT portfolio (including former Alere assets) spanning immunoassay, molecular, blood gas, and consumer diagnostics — competes head-to-head with Wondfo across most platform categories.
  • Hologic: US diagnostics and women's health specialist with molecular diagnostics (Panther), cytology/HPV testing, and rapid antigen tests — comparable to Wondfo in molecular POCT and select women's health/oncology adjacencies.
  • Bio-Rad Laboratories: Diversified life science and clinical diagnostics company with quality controls, blood bank reagents, and digital PCR — overlaps with Wondfo's molecular diagnostics and laboratory QC/reference measurement services.
  • Siemens Healthineers: Major global diagnostics and imaging incumbent with significant POCT and immunoassay presence (Atellica, epoc) — directly competes with Wondfo in chemiluminescence, blood gas, and immunochemistry hospital segments.
  • Roche Diagnostics: World's largest IVD player with extensive central-lab and POCT offerings across immunoassay, clinical chemistry, molecular diagnostics, and coagulation — overlaps with Wondfo's chemiluminescence, coagulation, and molecular diagnostics lines.

Direct peers

  • Acon Laboratories: US-headquartered IVD and POCT company with a comparable portfolio of rapid diagnostic tests across infectious disease, fertility, drugs of abuse, and clinical chemistry — overlapping directly with Wondfo's colloidal gold and consumer diagnostic lines.
  • Boditech Med: Korean POCT company focused on immunofluorescence and clinical chemistry analyzers with reagent menus spanning cardiovascular, inflammation, infectious disease, and hormones — directly comparable to Wondfo's Finecare platform.
  • SD Biosensor: Korean IVD/POCT specialist with strong overlap in immunofluorescence, rapid antigen tests, and infectious disease diagnostics — a close product-line competitor to Wondfo, especially in Africa and Southeast Asia.
  • Sinocare Inc. China-based IVD/POCT competitor with leadership in blood glucose monitoring and a growing portfolio in infectious disease and chronic disease diagnostics — overlaps with Wondfo's domestic Chinese POCT positioning and consumer health (Wondfo Health) initiatives.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Wondfo social profiles

Digital presence

Wondfo compliance and trust

Trust signal

Compliance5 records

Wondfo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wondfo leadership team

Management profile

Number of profiles

Profiles5 records

Wondfo subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Wondfo funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wondfo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wondfo

What does Wondfo do?

Wondfo develops and manufactures in vitro diagnostic (IVD) devices and reagents organized around nine proprietary technology platforms — Colloidal Gold, Immunofluorescence (Finecare), Chemiluminescence (ACCRE/SmarLumi), Coagulation, Blood Gas, Molecular Diagnostics, Pathology, HPLC Hemoglobin, and Electrochemistry — for point-of-care testing across infectious disease, cardiovascular, diabetes, oncology, fertility, drug-of-abuse, and chronic disease applications. The company also sells FDA-cleared consumer diagnostics (WELLlife COVID-19/Flu Home Test, SAFElife Fentanyl Test) in North America, and partners with global health programs for WHO-prequalified HIV and Malaria tests. Revenue is generated through instrument sales, recurring reagent consumption, government and WHO procurement, technology transfer/licensing for local production, and B2C retail sales.

Is Wondfo a public or private company?

Wondfo is a public company. It is classified as public and is currently operating.

When was Wondfo founded?

Wondfo was founded in 1992. It employs 1,001 to 5,000 people.

Where is Wondfo based?

Wondfo is headquartered in Guangzhou, China, in the Asia region.

How does Wondfo make money?

Four revenue lines are on record. POCT Instruments and Reagents are the primary driver. The others are consumer/Direct-to-Consumer Diagnostics, public Health and Government Procurement and local Manufacturing and Technology Transfer.

Who are Wondfo's main competitors?

Broad incumbents on record are QuidelOrtho, Abbott Diagnostics, Hologic, Bio-Rad Laboratories, Siemens Healthineers and Roche Diagnostics. Direct peers are Acon Laboratories, Boditech Med, SD Biosensor and Sinocare Inc..

Does Wondfo have an API?

No public API is recorded for Wondfo.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessdayNigeria’s pharma sector sees growing investment, but local manufacturing lagsNigeria's pharmaceutical sector is recording growing investor interest following federal government policies introduced in 2023 after the exit of multinational pharma companies, with $4.8 billion in potential investments attracted in 2024 and $2.2 billion committed in 2025, along with at least 10 strategic MoUs signed with global pharmaceutical companies including Vestergaard, Abbott, Wondfo, Siemens Healthineers, and Zipline. However, local manufacturing remains sluggish at approximately 38%, well below the government's 70% local production target for 2030, with manufacturers citing persistent high operating costs, limited access to credit and expensive borrowing, poor infrastructure, and bureaucratic delays as ongoing constraints despite the policy reforms.The Times of IndiaCity doc shares view on POCT at China meetDr Lokendra Gupta, director of Emergency Medicine at Medanta Hospital, spoke at the Global POCT Summit 2025 in Guangzhou, representing India. He shared insights on POCT innovations in emergency medicine and their role in strengthening emergency medicine in India. The summit, organized by Wondfo and IFCC, drew experts from over 30 countries.PR NewswireWondfo - v roce 2021 budou klíčem v boji proti pandemii COVID-19 protilátkové, antigenní a PCR testyWondfo Biotech Co., Ltd., headquartered in Guangzhou, China, issued a press release in February 2021 highlighting its portfolio of COVID-19 testing solutions, including antibody, antigen, and PCR tests, as essential tools for pandemic control. According to the release, the company has delivered over 50 million COVID-19 tests to 93 countries since the pandemic began, with health authorities in Brazil, Spain, Ireland, and Indonesia among those selecting Wondfo products for national and regional testing programs. The Brazilian Ministry of Health notably deployed Wondfo tests in population screening across 133 cities, while studies by Brown University and the University of California validated the company's antibody tests for sensitivity and specificity.PR NewswireWondfo - testes de anticorpos neutralizantes, testes de antígeno e PCR fundamentais na batalha contra a COVID-19 em 2021Wondfo, a Guangzhou-based biotech company, announced the expansion of its COVID-19 testing portfolio including neutralization antibody tests, antigen tests, and PCR tests to meet growing global demand as countries manage new infection waves and vaccination programs. Studies from Brown University and the University of California demonstrated that Wondfo's antibody tests achieved the highest sensitivity and specificity among all evaluated tests, with researchers in Brazil, France, and Australia reaching the same conclusions. The company has supplied over 50 million COVID-19 tests across 93 countries since the pandemic began, with products selected by health authorities in Spain, Brazil, Ireland, and Indonesia for national pandemic response programs.PR NewswireWondfo - Les tests d'anticorps neutralisants, les tests d'antigènes et la PCR sont essentiels dans la lutte contre la COVID-19 en 2021Wondfo (Guangzhou Wondfo Biotech Co.) announced it is accelerating production of neutralizing antibody, antigen, and PCR tests to meet global demand for COVID-19 testing in 2021, as countries roll out vaccination programmes alongside testing strategies. Studies by researchers at Brown University and the University of California found Wondfo's antibody tests achieved the highest sensitivity and specificity among evaluated tests, with health authorities in Spain, Brazil, Ireland, and Indonesia adopting them as primary testing tools. The company has supplied more than 50 million COVID-19 tests across 93 countries since the pandemic began.PR NewswireWondfo: тестирование на нейтрализующие антитела, тестирование на антигены и ПЦР-тестирование как ключевые элементы борьбы против COVID-19 в 2021 годуWondfo, a Guangzhou-based biotechnology company, announced it is scaling up production of neutralizing antibody tests, antigen tests, and PCR tests to meet growing global demand for COVID-19 testing as countries develop strategies to combat new infection waves amid vaccination programs. Since the pandemic began, Wondfo has supplied over 50 million COVID-19 tests to 93 countries, with its antibody tests adopted by health ministries in Spain, Brazil, Ireland, and Indonesia for national testing programs. The company also reports rising demand for neutralizing antibody tests as vaccination programs advance, which can help assess vaccine efficacy and immune response in vaccinated populations.